Virginia Klimek

Virginia Klimek is a clinical investigator specializing in TP53-mutated myelodysplastic syndromes and AML, a particularly challenging patient population with very poor outcomes using standard therapies. She has contributed to evaluation of APR-246 (eprenetapopt) in combination with azacitidine for TP53-mutated MDS in clinical trials. Her research characterizes the clonal dynamics of TP53-mutated hematopoietic cells and responses to novel therapeutic strategies. She is actively involved in developing rational combination approaches and supporting patients through clinical trials.